Erlotinib Improves Response of Glioblastoma Cells Resistant to Photodynamic Therapy
Author Information
Author(s): Olthoff Karen, Nigra Ayelén D., Milla Sanabria Laura N., Klekner Álmos
Primary Institution: Universidad Nacional de Río Cuarto (UNRC), INBIAS (CONICET-UNRC), Río Cuarto, Argentina
Hypothesis
The study aims to evaluate the response of T98G glioblastoma cells resistant to photodynamic therapy when EGFR activity is inhibited with erlotinib.
Conclusion
Erlotinib reduces the viability of glioblastoma cells resistant to photodynamic therapy by increasing the content of the photosensitizer PpIX.
Supporting Evidence
- Erlotinib combined with photodynamic therapy reduced cell viability in resistant glioblastoma populations.
- The content of the photosensitizer PpIX increased in resistant cells when treated with erlotinib.
- Erlotinib inhibited the proliferation of both parental and resistant T98G cells in 3D cultures.
- Wound closure was reduced in both parental and resistant T98G populations when treated with erlotinib.
Takeaway
Researchers found that a drug called erlotinib helps make stubborn brain cancer cells easier to treat when combined with light therapy.
Methodology
The study involved cell culture, viability assays, flow cytometry, and wound healing assays to assess the effects of erlotinib on glioblastoma cells.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website